Repurgenesis Co., LTD. will attend NVIDIA GTC 2026 in San Jose, California this March, where the company present our AI-powered drug repurposing technology. As one of the world's premit AI conferences, NVIDIA GTC brings together leading innovators in artifical intelligence, accelerated computing and lifie sciences.

At the conference, Repurgenesis will showcase a poster presentation demonstrating how our proprietary AI-driven platform accelerate the discovery of new therapeutic indicatiopns for existing drugs.

Poster ID: P81062

The Repurgenesis AI platform integrates multi-modal biomedical data, advanced machine learining algorithms and high-performance computing to systematically identify novel clinical opportunities for approved or iff-patent drugs. By combining AI with drug repurposing strategies, the platform aims to significantly reduce the cost required to bring new therapies to patients.

Repurgensis id dedicated to advancing next-generation drug discovery throigh artifical intelligence and strategic drug repurposimg. The company continues to develop our integrated AI dug repurposing platform while exploring partnerships with global pharmaceutical and technology companies.